Evidence map›Paper›PMID 24577825›Full record

ArticleCroatian medical journal2014

Estrogen receptor 1 gene (TA)n polymorphism is associated with lone atrial fibrillation in men.

Karlo Golubić, Anton Šmalcelj, Jadranka Sertić, Ljiljana Juričić

Open access · diamondAbstract read
In one paragraph

Article in Croatian medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Network Pharmacology and Pharmacological Mechanism of CV-3 in Atrial Fibrillation.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Karlo GolubićKarlo Golubic, Department of Cardiovascular Diseases, University Hospital Center, School of Medicine, University of Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia, karlo.golubic@gmail.com.
Anton Šmalcelj
Jadranka Sertić
Ljiljana Juričić
University of Zagreb · HRUniversity Hospital Centre Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine the association between the number of thymine-adenine (TA)n dinucleotide repeats in the promoter region of the gene coding for the estrogen receptor alpha (ESR1) and the prevalence of lone atrial fibrillation (AF) in men.

methodsWe conducted a case-control study involving 89 men with lone AF and 166 healthy male controls. The ESR1 genotype was established by polymerase chain reaction and capillary electrophoresis. To assess the association of ESR1 genotype with AF, logistic regression models were built with AF as outcome.

resultsMen with lone AF had significantly greater number of (TA)n repeats of single alleles than controls (mean ± standard deviation, 19.2 ± 4.2 vs 18 ± 4.3, P = 0.010). After adjustment for other factors, a unit-increase in (TA)n repeat number was associated with a significantly greater likelihood of AF (odds ratio 1.069; 95% confidence interval 1.024-1.116, P=0.002).

conclusionsOur results indicate that a greater number of (TA)n repeats in the promoter region of ESR1 is associated with a significantly increased likelihood of lone atrial fibrillation in men.

Indexed as

Polymorphism, GeneticAllelesAtrial FibrillationBlood PressureCase-Control StudiesDinucleotide RepeatsElectrocardiographyEstrogen Receptor alphaGenotypeHumansLogistic ModelsMaleMiddle AgedPolymerase Chain ReactionPromoter Regions, GeneticESR1 protein, humanEstrogen Receptor alpha

Identifiers

PMID24577825
PMCPMC3944416
OpenAlexW2124519590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.